Vetoquinol is down almost 1% following the animal health laboratory's announcement of sales of €136 million for the third quarter of 2023, up 1.3% on a reported basis and 5.1% at constant exchange rates.

Sales of essential products rose by 9% to €81 million (+12.2% at constant exchange rates), driven by the development of the existing portfolio and the ongoing launches of Felpreva in Europe and Simplera in the USA.

In a global animal health market still driven by prices, we are continuing to launch and ramp up our new essentials, which will drive our long-term strategy", comments CEO Matthieu Frechin.

Copyright (c) 2023 CercleFinance.com. All rights reserved.